|Title||SmithKline Beecham Hepatitis A Vaccine, Havrix R, adult dose|
00.0001.002.01 - Hepatitis A Vaccine, Havrix, 1 mL vial
00.0001.002.02 - Green flip cap
00.0001.002.03 - Original cardboard box
Small glass vial (empty) with green flip cap. Cardboard box is white with purple, black, and green ink.
|Collection||Office of Technology Transfer|
|Caption||SmithKline Beecham Hepatitis A Vaccine, Havrix R, adult dose|
From "NIAID Scientists Enjoy Fruits of Vaccine Success," by Marion E. Glick, The NIH Record, June 6, 1995, page 3: "NIAID’s Drs. Robert H. Purcell, Suzanne U. Emerson and Jeffrey I. Cohen, and the FDA’s Drs. Stephen Feinstone and Richard Daemer, of the Center for Biologics Evaluation and Research, developed and patented a hepatitis A virus (HAV) and related technology used to develop the vaccine. Purcell is chief of the NIAID Laboratory of Infectious Diseases hepatitis viurses section, in which Emerson works. Cohen works in the NIAID Laboratory of Clinical Investigation. Dr. John Ticehurst of Johns Hopkins School of Medicine and Dr. Ian Gust of Commonwealth Serum Laboratories of Melbourne, Australia, also collaborated on the patents....The patents cover a strain of human HAV, HM175, an attenuated form of HM175 and the methods developed to isolate and grow the viruses in cultures of kidney cells derived from African green monkeys. In 1985, based on the scientific and commercial potentials of the NIAID inventions, SmithKline Beecham took a nonexclusive license on the patents and, in 1986, established a cooperative research and development agreement to develop HAVRIX, the world’s first commercially available HAV vaccine. HAVRIX uses an inactivated HM175 strain of HAV. In 1994, SmithKline received the European Prix Gallen award for HAVRIX in honor of its overall contribution to medicine in terms of safety, efficacy and innovation. Currently, HAVRIX is registered in more than 40 countries. Prior to the availability of this vaccine, only passive immunization with blood-derived immunoglobulin could offer protection against HAV, and then only for 2 to 5 months. The vaccine offers protection after one dose. With a booster in 6 to 12 months, the vaccine is predicted to protect for up to 10 years. With more than 10 million cases each year worldwide, hepatitis A is the most widespread of the viral hepatitis infections. HAV is transmitted commonly by person-to-person contact and by contaminated food and water. The resulting liver disease usually is mild and does not become chronic. Occasionally, HAV infection leads to liver failure and death."
NDC 58160-837-01. Licensed under L-380-91/0; L-075-94/0. The virus is grown in MRC5 human diploid cells and cells are lysed. The resulting suspension is ultrafiltered and gel permeated chromatographed. The first vaccine for Hepatitis A.
|Number of images||1.0|
NIH; NIAID (National Institute of Allergy and Infectious Diseases) (1955-present)
Food and Drug Administration (U.S.)
Johns Hopkins School of Medicine
Commonwealth Serum Laboratories
|NIH Property #||none|
|Old NIH Property #||none|
Kapikian, Albert Z.
Purcell, Robert H.